ADS-AMT-MS201
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Description
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once daily at bedtime for the treatment of walking impairment in MS.
ADS-5102 is designed to deliver its primary treatment effect during the day, and potentially reduce the adverse events of immediate-release amantadine when the patient is asleep.
Currently enrolling
Who may be eligible to participate? Patients aged 18 to 70 years with a confirmed diagnosis of Multiple Sclerosis. Patients must be on a stable regimen of medication taken specifically to treat MS for at least 30 days prior to screening.
Investigator: Theodore Brown, M.D.
For More Information: Anna Fierro - 425.899.5387 AMFierro@evergreenhealth.com
No comments:
Post a Comment